BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

REG1 Anticoagulation System: Phase IIb data

The double-blind reversal, active-controlled, international Phase IIb RADAR trial in 640 evaluable ACS patients undergoing cardiac catheterization showed that Regado's REG1 Anticoagulation System met 1 of 2 co-primary endpoints. On the first co-primary endpoint, the arm consisting of 100% reversal of Factor IXa inhibition significantly reduced the rate of total ACUITY bleeding at 30 days vs. the 25% reversal arm (30.4% vs. 65%, p<0.0001). The 100% arm consisted of 1 mg/kg IV pegnivacogin followed by 1 mg/kg IV anivamersen, while the 25% reversal...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >